BioSpace News Archive

BD, a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers, is celebrating National Health Center Week by honoring the six community health centers in the U.S. that earned this year’s Innovations in Care Award, recognizing their success in helping vulnerable patients manage complex chronic diseases and improve overall health.

ImmaticsN.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting period.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results as of and for the second quarter ended June 30, 2021.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported financial results for the second quarter ended June 30, 2021 as well as certain other business highlights.

EyePoint Pharmaceuticals, Inc. today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021.

Rezolute, Inc. today announced that the Company has initiated dosing in a Phase 1b multiple-ascending dose study of RZ402, Rezolute’s investigational oral plasma kallikrein inhibitor (PKI) for the treatment of diabetic macular edema (DME).

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced the publication of an exploratory analysis evaluating the safety of OLINVYK injection and IV morphine, using data from the OLINVYK Phase 3 program.

Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified.

Finch Therapeutics Group, Inc. today announced that Takeda Pharmaceutical Company Limited (“Takeda”) has elected to accelerate the transition of development responsibility for the FIN-524 ulcerative colitis development program.

Fulcrum Therapeutics, Inc. today provided a business update and reported financial results for the second quarter of 2021.